Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma. Mosun SC shows positive ORR and CMR rates in first-line MZL, offering an effective, outpatient-friendly treatment option. Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025. Brexu-cel shows a significant 5-year OS rate in R/R B-ALL patients, with survival benefits across key subgroups in ZUMA-3.
Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds. Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses. Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data. Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system. The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained. Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma. Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma. Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough. Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity. The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy. At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free. AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care. The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET. Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL. Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.